GlassScriptPhysician profile
Thomas D Lei
NPI 1225001027
$23,465.58
in general payments reported to CMS, 2019-2025
22 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $11.56 · 2021: $5,535 · 2022: $8,965 · 2023: $3,391 · 2024: $4,144 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,017 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,110 · Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,017.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,109.82 |
| Food and Beverage | $766.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $19,999.03 | 2019-2024 | Da Vinci Sp, Da Vinci Surgical System |
| Pulmonx Corporation | $1,362.09 | 2022 | |
| Ethicon INC. | $628.98 | 2019-2021 | |
| Medtronic, INC. | $203.01 | 2021 | |
| Veran Medical Technologies, INC. | $199.88 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $183.11 | 2019-2025 | Imfinzi |
| Glaxosmithkline, LLC. | $163.72 | 2019-2025 | Nucala |
| Olympus America INC. | $137.81 | 2021 | |
| Boston Scientific Corporation | $123.03 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $86.49 | 2025 | Uptravi, Opsumit, Opsynvi |
| Verona Pharma, INC. | $64.00 | 2025 | Ohtuvayre |
| Covidien LP | $54.16 | 2019 | |
| Insmed, INC. | $39.33 | 2025 | Brinsupri, Arikayce |
| Janssen Biotech, INC. | $34.30 | 2022 | |
| Daiichi Sankyo INC. | $28.75 | 2025 | Enhertu |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $26.26 | 2025 | |
| Lilly USA, LLC | $25.09 | 2025 | |
| Eisai INC. | $24.80 | 2022 | |
| Kite Pharma, INC. | $24.31 | 2025 | Yescarta |
| Blue Earth Diagnostics | $22.34 | 2022 | |
| Merck Sharp & Dohme LLC | $22.03 | 2022 | |
| Electromed, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.